TCTR20141019001招募中4 期
Effect of switching efavirenz to rilpivirine in treatment of HIV- infected patients with dyslipidemia
Infectious disease association of Thailand0 个研究点目标入组 52 人开始时间: 2014年10月19日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Inclusion Criteria:
- •-HIV-1 infected adults, who were receiving antiretroviral therapy including efavirenz for at least 6 months
- •-plasma HIV RNA<50 cp/ml during the previous 6 months
- •-Severe dyslipidemia with Low-Density Lipoprotein cholesterol (LDL-c) >130 mg/dL in the presence of at least one of the 3 following coronary heart disease (CHD) risk factors: age>45 among males or age>55 among females, hypertension, current smoking, family history of CHD,DM
- •-Low-Density Lipoprotein cholesterol (LDL-c)>160 mg/dL regardless of CHD risk factors.
- •-Diagnosed dyslipidemia and current treatment with lipid lowering agent
排除标准
- •-Receive ongoing therapy with proton pump inhibitor, rifamycin, carbamazepine, oxcarbamazepine, phenobarbital, phenytoin,systemic steroid and St John’s wort
- •-Asparate aminotransferase (AST) or alanine aminotransferase (ALT) >3N
- •-Pregnancy
- •-Severe depression
研究者
相似试验
尚未招募
4 期
Effect after Switching from Efavirenz to Rilpivirine on Liver Steatosis Among People Living with HIV with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled TrialWe aimed at comparing the impact of switching from efavirenz to rilpivirine in patients receiving efavirenz plus 2 nucleoside analogues versus continuing with the same therapy on hepatic steatosis as measured by controlled attenuation parameter (CAP) among HIV-infected patients with NAFLD.EfavirenzRilpivirineSwitchingHIVNAFLDCAPFatty liver diseaseTCTR20210403003Thai AIDs Society54
Unknown
2 期
Rilpivirine in Virologically Suppressed AdolescentsHIVNCT03033368Mahidol University100
进行中（未招募）
1 期
Efficacy of Switching to Lopinavir/Ritonavir (Kaletra) in Improving Cognitive function in patients treated with Efavirenz (EFV) (SLICE Study)EUCTR2011-005581-37-GBThe Newcastle upon Tyne Hospitals NHS Foundation Trust16
已完成
不适用
Efficacy of Rilpivirine-based Regimens as Switch Therapy From Nevirapine-based Regimens in HIV-infected PatientsEfficacy of Rilpivirine-based Regimens as Switch TherapyNCT03664440Mahidol University106
未知
不适用
Efficacy and safety on effects of ribavirin with sofosbuir and ledipasvir combination therapy for patients who failed to daclatasvir and asunaprevir combination therapyPatients with chronic hepatitis C, who failed to DCV/ASV therapyJPRN-UMIN000021790St. Marianna University School of Medicine20